Commonwealth Equity Services LLC Sells 107,533 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Commonwealth Equity Services LLC decreased its holdings in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 39.8% in the 2nd quarter, according to its most recent 13F filing with the SEC. The fund owned 162,770 shares of the company’s stock after selling 107,533 shares during the period. Commonwealth Equity Services LLC’s holdings in Teva Pharmaceutical Industries were worth $2,645,000 at the end of the most recent reporting period.

A number of other large investors have also made changes to their positions in the company. Sequoia Financial Advisors LLC increased its position in shares of Teva Pharmaceutical Industries by 0.7% in the 2nd quarter. Sequoia Financial Advisors LLC now owns 111,575 shares of the company’s stock valued at $1,813,000 after buying an additional 826 shares in the last quarter. Edmond DE Rothschild Holding S.A. increased its position in shares of Teva Pharmaceutical Industries by 4.0% in the 1st quarter. Edmond DE Rothschild Holding S.A. now owns 24,495 shares of the company’s stock valued at $346,000 after buying an additional 947 shares in the last quarter. Oppenheimer & Co. Inc. increased its position in shares of Teva Pharmaceutical Industries by 9.6% in the 1st quarter. Oppenheimer & Co. Inc. now owns 13,522 shares of the company’s stock valued at $191,000 after buying an additional 1,180 shares in the last quarter. QRG Capital Management Inc. increased its position in shares of Teva Pharmaceutical Industries by 0.8% in the 2nd quarter. QRG Capital Management Inc. now owns 144,938 shares of the company’s stock valued at $2,355,000 after buying an additional 1,191 shares in the last quarter. Finally, GAMMA Investing LLC increased its position in shares of Teva Pharmaceutical Industries by 105.7% in the 2nd quarter. GAMMA Investing LLC now owns 3,388 shares of the company’s stock valued at $55,000 after buying an additional 1,741 shares in the last quarter. Institutional investors own 54.05% of the company’s stock.

Insider Transactions at Teva Pharmaceutical Industries

In other news, insider Eric A. Hughes sold 24,537 shares of the stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $17.25, for a total transaction of $423,263.25. Following the completion of the transaction, the insider now directly owns 45,060 shares in the company, valued at approximately $777,285. The transaction was disclosed in a document filed with the SEC, which is available at this link. In related news, Director Roberto Mignone sold 519,000 shares of the firm’s stock in a transaction dated Tuesday, June 18th. The shares were sold at an average price of $17.03, for a total value of $8,838,570.00. Following the completion of the sale, the director now directly owns 981,000 shares in the company, valued at approximately $16,706,430. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Eric A. Hughes sold 24,537 shares of the firm’s stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $17.25, for a total transaction of $423,263.25. Following the completion of the sale, the insider now owns 45,060 shares of the company’s stock, valued at $777,285. The disclosure for this sale can be found here. Company insiders own 0.55% of the company’s stock.

Analysts Set New Price Targets

A number of research firms recently commented on TEVA. StockNews.com upgraded shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 3rd. Bank of America increased their target price on Teva Pharmaceutical Industries from $18.00 to $21.00 and gave the stock a “buy” rating in a report on Thursday, May 30th. Argus upgraded Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and set a $20.00 target price for the company in a report on Wednesday, July 10th. Barclays increased their target price on Teva Pharmaceutical Industries from $21.00 to $22.00 and gave the stock an “overweight” rating in a report on Thursday, August 1st. Finally, Jefferies Financial Group increased their target price on Teva Pharmaceutical Industries from $19.00 to $23.00 and gave the stock a “buy” rating in a report on Thursday, June 27th. Two investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $18.89.

Teva Pharmaceutical Industries Trading Up 2.5 %

Teva Pharmaceutical Industries stock opened at $17.96 on Thursday. The firm has a 50-day moving average of $17.47 and a 200-day moving average of $15.85. Teva Pharmaceutical Industries Limited has a one year low of $8.06 and a one year high of $19.08. The company has a debt-to-equity ratio of 2.52, a current ratio of 0.89 and a quick ratio of 0.59. The company has a market cap of $20.35 billion, a price-to-earnings ratio of -43.80, a P/E/G ratio of 1.25 and a beta of 0.88.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings data on Wednesday, July 31st. The company reported $0.58 EPS for the quarter, topping analysts’ consensus estimates of $0.55 by $0.03. Teva Pharmaceutical Industries had a negative net margin of 2.73% and a positive return on equity of 39.66%. The company had revenue of $4.16 billion during the quarter, compared to the consensus estimate of $3.99 billion. On average, equities analysts expect that Teva Pharmaceutical Industries Limited will post 2.35 earnings per share for the current fiscal year.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.